Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30189641 | 0.82 | KCNH2 (0.33) | OPRL1KCNH2GRIN2BOPRM1OPRD1 | |
| SCHEMBL1843463 | 0.78 | ALDH1A1 (0.34) | KCNH2GRIN2B | |
| SCHEMBL633353 | 0.78 | SLC6A2 (0.43) | OPRL1KCNH2GRIN2BOPRM1OPRD1 | |
| SCHEMBL9429598 | 0.75 | OPRL1 (0.34) | OPRL1HDAC4 | |
| SCHEMBL7968110 | 0.73 | HTR6 (0.40) | KCNH2MEN1CYP3A4KMT2A | |
| SCHEMBL29435414 | 0.73 | HTR6 (0.40) | KCNH2MEN1CYP3A4KMT2A | |
| SCHEMBL7356160 | 0.73 | CHRNB4 (0.33) | — | |
| SCHEMBL9429855 | 0.72 | OPRL1 (0.32) | OPRL1HDAC4 | |
| SCHEMBL7458612 | 0.70 | OPRM1 (0.34) | OPRM1KMT2A | |
| SCHEMBL8812050 | 0.69 | OPRM1 (0.36) | GRIN2BOPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670375-B2 | Particularly, 8-aza-, 8-carbo- and 8-oxo- tropanes having 6-or 7-substituents; preferred are the dopamine transporter, the serotonin transporter and the norepinephrine transporter. | ORGANIX, INC. | 2003-12-30 | — | — | US | disclosed |
| US-20020010207-A1 | Tropane analogs and methods for inhibition of monoamine transport | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2002-01-24 | — | — | US | disclosed |
| WO-1995011901-A9 | SUBSTITUTED 2-CARBOXYALKYL-3-(FLUOROPHENYL)-8-(3-HALOPROPEN-2-YL) NORTROPANES AND THEIR USE AS IMAGING AGENTS FOR NEURODEGENERATIVE DISORDERS | — | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010207-A1 | Tropane analogs and methods for inhibition of monoamine transport | SLC6A2, SLC6A4, SLC6A3 | OPRL1 175/4885HDAC4 3069/4885ABCB1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.